DeepMed Research

BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

Rituximab for GVHD

Phase 2

Withdrawn

Conditions: Graft vs Host Disease
Alogenic Hematopoietic Transplant

Interventions: Drug: Rituximab

First Posted Date: 2007-12-21

Last Posted Date: 2012-07-09

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT00578591

Locations: 🇺🇸
Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Phase 1

Terminated

Conditions: Severe Combined Immunodeficiency Disease
Severe Primary Immunodeficiency Disorder
Undefined T Cell Deficiency Disorder
Wiskott-Aldrick Syndrome

Interventions: Biological: Campath -1H
Drug: Fludarabine
Biological: Anti-CD45
Procedure: Stem cell infusion

First Posted Date: 2007-12-21

Last Posted Date: 2013-07-02

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 3

Registration Number: NCT00579137

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease

Phase 2

Completed

Conditions: Chronic Granulomatous Disease

Interventions: Drug: Busulfan
Biological: Alemtuzumab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Cyclosporine
Procedure: Stem Cell Infusion

First Posted Date: 2007-12-21

Last Posted Date: 2018-11-09

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 15

Registration Number: NCT00578643

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE

Not Applicable

Terminated

Conditions: Lymphoma, Non-Hodgkin
Leukemia
Lymphoma, Hodgkin
Cancer
Lymphoma

Interventions: Drug: Ara C
Drug: Mesna
Drug: Cyclophosphamide
Radiation: TBI-Total Body Irradiation

First Posted Date: 2007-12-21

Last Posted Date: 2016-04-22

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 26

Registration Number: NCT00578461

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Phase 2

Terminated

Conditions: Aplastic Anemia

Interventions: Drug: Cytoxan
Drug: Campath
Radiation: Total Body Irradiation (TBI)
Drug: FK-506
Drug: Methotrexate
Procedure: Stem cell infusion

First Posted Date: 2007-12-21

Last Posted Date: 2016-04-22

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 22

Registration Number: NCT00578903

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

Not Applicable

Terminated

Conditions: Leukemia
Hodgkin Lymphoma
Non Hodgkin Lymphoma
Myeloproliferative Disorders

Interventions: Drug: ARA C
Drug: Cyclophosphamide
Drug: MESNA
Radiation: Total Body Irradiation (TBI)
Biological: Campath-1h
Procedure: Stem Cell Infusion

First Posted Date: 2007-12-21

Last Posted Date: 2016-04-22

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT00578539

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

Not Applicable

Terminated

Conditions: Thalassemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Campath 1H
Drug: Cyclophosphamide
Drug: MESNA

First Posted Date: 2007-12-21

Last Posted Date: 2020-05-01

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 10

Registration Number: NCT00578292

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Multiple Myeloma
Lymphoproliferative Disorders
Hematologic Diseases
Myelodysplastic and Myeloproliferative Disorders
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Plasma Cell Dyscrasia

Interventions: Drug: Campath
Drug: Busulfan
Drug: Fludarabine
Procedure: Hematopoietic stem cell infusion
Drug: FK-506

First Posted Date: 2007-12-21

Last Posted Date: 2016-05-04

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 4

Registration Number: NCT00579111

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Effect of Vitamin C on Iron Absorption

Not Applicable

Completed

Conditions: Iron Deficiency

Interventions: Dietary Supplement: Vitamin C

First Posted Date: 2007-12-11

Last Posted Date: 2020-06-26

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 22

Registration Number: NCT00570895

Locations: 🇺🇸
Children's Nutrition Research Center, Houston, Texas, United States

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

Phase 2

Completed

Conditions: ALL
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia
Myeloproliferative Disorder
Hodgkin Lymphoma
Non-malignant Diseases Requiring Allogeneic HSCT
AML
Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Non-Hodgkin Lymphoma

Interventions: Biological: IL-2

First Posted Date: 2007-10-04

Last Posted Date: 2018-05-04

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 25

Registration Number: NCT00539695

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy